In a 50-year-old male with a 25‑year smoking history (1 pack per day), hypertension (blood pressure 140/90 mmHg), elevated LDL cholesterol, and a BMI of 21, what is the most appropriate first step to reduce cardiovascular risk?

Complete Smoking Cessation is the Most Appropriate First Step

For this 50-year-old male with symptomatic cardiovascular disease (chest discomfort and dyspnea with exertion), hypertension, and severely elevated LDL, the most appropriate first step to reduce cardiovascular risk is prescribing bupropion (Option A) as part of a comprehensive smoking cessation program with counseling and follow-up support.

Why Smoking Cessation Takes Priority

Stopping smoking after cardiovascular symptoms is the single most effective preventive measure for reducing morbidity and mortality 1. The evidence shows:

• Immediate mortality benefit: Smoking cessation reduces myocardial infarction risk by 43% (RR 0.57) and the composite endpoint of death/MI by 26% (RR 0.74) compared to continued smoking 1
• Rapid risk reduction: Significant morbidity reductions occur within the first 6 months of cessation 1
• No safe level: There is no lower limit for deleterious cardiovascular effects from smoking—any reduction short of complete cessation provides minimal benefit 1

This patient's symptoms (chest discomfort and shortness of breath with exertion) combined with his risk factors suggest he likely has established coronary artery disease, making him a secondary prevention candidate where smoking cessation has the strongest evidence base.

Why Bupropion Specifically

The 2016 European Guidelines on CVD Prevention establish that pharmacotherapy should be offered when behavioral interventions alone are insufficient 1. Bupropion has equivalent efficacy to nicotine replacement therapy and increases long-term cessation rates by 50-70% 1. The "Five As" approach (Ask, Advise, Assess, Assist, Arrange) should guide implementation 1:

1. Ask about tobacco use at every visit (Class I, Level B) 2
2. Advise to quit completely at every visit (Class I, Level A) 2
3. Assess willingness and degree of addiction
4. Assist with counseling, developing a quit plan, and pharmacotherapy including bupropion (Class I, Level A) 2
5. Arrange follow-up support (Class I, Level C) 2

Why Not the Other Options

Option B (holding management) is dangerous—this patient is already symptomatic with multiple cardiovascular risk factors. Waiting for further symptoms risks acute coronary events or death.

Option C (low-intensity statin) addresses only one risk factor and uses suboptimal therapy. While his LDL of 8.2 mmol/L (approximately 317 mg/dL) absolutely requires aggressive statin therapy, the guidelines recommend high-intensity statins for patients with clinical cardiovascular disease to achieve LDL <100 mg/dL, with <70 mg/dL being reasonable for very high-risk patients 2, 3. However, statin therapy should be initiated concurrently with—not instead of—smoking cessation.

Option D (gradual smoking reduction) contradicts the evidence. Smoking reduction has not been shown to increase the probability of future cessation 1. The dose-response relationship between smoking and cardiovascular risk has no safe threshold 1. Research demonstrates that even among hypertensive patients, smoking exacerbates cardiovascular and all-cause mortality in a dose-dependent manner 4.

The Complete Clinical Approach

While the question asks for the "most appropriate first step," this patient requires simultaneous interventions:

Immediate Actions:

1. Initiate smoking cessation with bupropion plus counseling (primary answer)
2. Start high-intensity statin therapy (not low-intensity) to target LDL <70 mg/dL given symptomatic disease 2, 3
3. Initiate antihypertensive therapy with beta-blockers and/or ACE inhibitors for BP >140/90 mmHg (Class I, Level A) 2, 3
4. Urgent cardiovascular evaluation for his exertional symptoms—he may need stress testing or coronary angiography

Why Smoking Cessation Comes First:

The synergistic effect between smoking and hypertension dramatically amplifies risk. Research shows that smokers with stage 3 hypertension who smoke ≥20 pack-years have a 3.06-fold increased risk of CVD mortality compared to never-smokers with stage 1 hypertension 4. This patient has a 25 pack-year history, making the interaction particularly dangerous.

Critical Pitfalls to Avoid

• Never recommend gradual reduction instead of complete cessation—it provides false reassurance without meaningful risk reduction
• Don't delay pharmacotherapy for smoking cessation—the combination of counseling plus medication (bupropion, varenicline, or NRT) is significantly more effective than counseling alone 1
• Don't use low-intensity statins in symptomatic patients—this represents undertreatment of established cardiovascular disease
• Don't address only one risk factor—while smoking cessation is the priority, this patient needs comprehensive risk factor modification including aggressive lipid lowering and blood pressure control initiated simultaneously

The evidence unequivocally supports that complete smoking cessation with pharmacological assistance provides the greatest mortality and morbidity benefit for this high-risk patient 1.